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Abstract: INTRODUCTION Oral propranolol has improved the treatment of infantile hemangiomas,
and a pediatric oral solution of propranolol has recently been licensed in the USA and Europe. In very
preterm infants, infantile hemangiomas are associated with the occurrence of retinopathy of prematurity
(ROP), and both diseases share a peculiar time course, featuring a lag phase after birth followed by rapid
growth and then gradual regression. OBJECTIVES To identify clinical studies evaluating the use of oral
propranolol in preterm infants with ROP. RESULTS Two small bicentric, pilot, randomized controlled
trials found a nonsignificant reduction of ROP requiring intervention by laser treatment or bevacizumab
injection of similar magnitude. Together, 6 of 35 (17%) infants who had been receiving oral propranolol
underwent ROP intervention, as opposed to 14 of 36 (39%) controls (relative risk 0.42, 95% CI: 0.15-1.16).
Randomized controlled trials are ongoing that investigate early preventive oral propranolol starting at
1 week of age and propranolol eye drops in preterm infants with stage 2 ROP. CONCLUSION Further,
large interventional studies are required to determine the clinical benefit-risk ratio of oral propranolol to
prevent vision-threatening ROP in very preterm infants. © 2015 S. Karger AG, Basel.
DOI: 10.1159/000381659
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interventional studies are required to determine the clinical 
benefit-risk ratio of oral propranolol to prevent vision-threat-
ening ROP in very preterm infants.  © 2015 S. Karger AG, Basel 
 Introduction 
 The medical use of the β-adrenergic inhibitor propran-
olol in humans started over 50 years ago  [1] and led to the 
award of the Nobel prize for medicine and physiology to 
its developer, the Scottish physician and pharmacologist 
James W. Black, in 1988. Propranolol is on the World 
Health Organization’s list of essential medicines and is 
widely used in adult patients, children, and infants. Its 
long-standing pediatric indications include prevention of 
paroxysmal supraventricular tachycardia, prevention of 
sudden ventricular fibrillation in long QT syndrome, pre-
vention of blue spells in tetralogy of Fallot, and treatment 
of hypertension in children with renal or cardiovascular 
disease. The serendipitous discovery of regression of in-
fantile hemangiomas in infants treated with oral propran-
olol for hypertrophic cardiomyopathy in 2007  [2] , fol-
lowed by over 30 open-label trials  [3] and two placebo-
controlled trials  [4, 5] , has led to the approval of an oral 
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propranolol solution for the treatment of infantile heman-
gioma by the Federal Drug Administration in the USA, a 
Paediatric Use Marketing Authorization by the European 
Medicines Agency, and SwissMedic approval in 2014.
 Safety and Pharmacokinetics 
 The use of oral propranolol is well established in the 
treatment of congenital thyrotoxicosis, and it is given pro-
phylactically over extended periods of time to neonates 
with paroxysmal supraventricular tachycardia, long QT 
syndrome, or tetralogy of Fallot. Reported side effects of 
oral propranolol in infants include diarrhea, bronchitis, in-
somnia, nightmares, bradycardia, hypotension, and hypo-
glycemia  [6] , and in rare cases hyperkalemia upon com-
mencement of propranolol  [7, 8] . In a study specifically re-
porting on treatment of very low birth weight infants with 
oral propranolol for infantile hemangiomas  [9] , no side ef-
fects were noted, but the overall number of preterm infants 
included was small (n = 9). A pharmacokinetic study of oral 
propranolol in term and preterm infants receiving total 
daily dosages of 2 mg/kg  [10] demonstrated lower elimina-
tion half-lives of propranolol and apparent total body clear-
ances than those reported in adults. However, maximal, 
minimal, and average concentrations, times of maximal 
concentration, and areas under the time-concentration 
curves were similar to those observed in adults when evalu-
ated at steady state, without differences between newborns 
with different gestational ages or between girls and boys. 
 Infantile Hemangioma and Retinopathy of 
Prematurity  
 The mechanism of action by which propranolol affects 
the growth of infantile hemangiomas and leads to their 
regression is poorly understood. Infantile hemangiomas 
are characterized by a peculiar natural course. They start 
to become apparent at 1–2 months of age, display a pe-
riod of rapid growth peaking at 3–5 months of age, and 
show gradual involution thereafter  [11, 12] . This pattern 
is reminiscent of the natural history of retinopathy of pre-
maturity (ROP) which is absent during the first 4–6 weeks 
of life, followed by a phase of rapid vessel proliferation 
and sequential gradual resolution  [13, 14] . Infantile hem-
angiomas are more common in very preterm infants, as 
opposed to term infants, and there is an association be-
tween infantile hemangioma and ROP  [15] . The clinical 
similarities of infantile hemangioma and ROP and the 
successful treatment of infantile hemangiomas with oral 
propranolol have prompted experiments with various 
mouse strains investigating the effects of propranolol on 
oxygen-induced retinopathy which bears many hall-
marks of ROP. In C57Bl/6J mice, systemic propranolol 
reduced retinal neovascularization and reduced produc-
tion of vascular endothelial growth factor (VEGF) in hy-
poxic retinas, without affecting VEGF production in nor-
moxic retinas or other organs  [16] . In contrast, propran-
olol failed to suppress retinal neovascularization in the 
same model when using 129S6 mice  [17] , which differ 
from C57Bl/6J mice by a dramatic upregulation of β 3 -
adrenoreceptors after return to room air. 
 Oral Propranolol in Infants with ROP: Randomized 
Controlled Trials 
 We searched the International Clinical Trials Registry 
Platform of the World Health Organization (http://apps.
who.int/trialsearch/) that collects updated trial registra-
tion data sets provided by national or supranational reg-
istries and the US National Library of Medicine (http://
www.ncbi.nlm.nih.gov/pubmed) using the terms ‘pro-
pranolol’ and ‘retinopathy of prematurity’ in October 
2014, and identified two completed randomized con-
trolled trials that have published results  [18, 19] as well as 
two ongoing trials.
 Pilot Randomized Controlled Trials with Published 
Results  
 The bicenter trial (NCT01238471) carried out in Haifa 
and Jerusalem, Israel  [18] , randomized 20 infants with a 
gestational age of 24–28 weeks at birth with stage 2 or 
more ROP (zone II) or stage 1 ROP (zone I) to oral pro-
pranolol (starting dose: 0.5 mg/kg/day, divided in 3 doses, 
incrementally increased to 1.5 mg/kg/day) or placebo un-
til hospital discharge, full retinal vascularization, or ROP 
intervention by laser treatment or bevacizumab injection 
(on average 16 ± 7 days). The short study report does not 
provide sufficient methodological details to reliably as-
sess the risk of bias. Two of the 10 infants randomized to 
oral propranolol underwent ROP treatment, as opposed 
to 4 of the 10 control infants (p = 0.63, relative risk 0.44, 
95% CI: 0.11–1.78). In the oral propranolol group, 4 out 
of 19 eyes underwent treatment (all by laser), as opposed 
to 8 out of 19 eyes in the control group (laser: n = 5, bev-




























   
   




















 Propranolol in ROP Neonatology 2015;108:49–52
DOI: 10.1159/000381659
51
 The bicenter trial (NCT0107915/ISRCTN18523491) 
carried out in Firenze and Milano, Italy  [19] computer-
randomized 52 preterm infants with a gestational age of 
23–31 weeks at birth with ROP stage 2 to oral propranolol 
(2 mg/kg/day in 4 divided doses in infants 26–31 weeks’ 
gestational age at birth; 1 mg/kg/day in 4 divided doses in 
infants 23–25 weeks’ gestational age) or control until full 
retinal vascularization (on average 66 ± 33 days). Alloca-
tion was concealed. One infant who initially was enrolled 
in the treated group developed serious adverse effects 
from propranolol on the first day of treatment was moved 
into the control group. One propranolol-treated infant 
died 9 days after enrolment and thus presumably before 
reaching the endpoint, while 2 control infants died at 61 
and 87 days after enrolment, with the relationship to the 
endpoint being unclear. Neonatologists and nurses, but 
not ophthalmologists and data analysts, were aware of the 
allocation. Four of 25 infants analyzed who received pro-
pranolol ultimately underwent ROP treatment, as op-
posed to 10 of 26 controls (p = 0.12). This amounts to a 
relative risk of 0.42 with a 95% CI of 0.15–1.16 (errone-
ously given as 0.31–0.58 in the manuscript). No intention-
to-treat analysis was presented, and no attempt was made 
to evaluate the combined endpoint ‘death or ROP inter-
vention’. In the propranolol group, 8 out of 50 eyes had 
laser treatment, as opposed to 19 out of 52 eyes in the con-
trol group. Rescue treatment by bevacizumab was done in 
3 out of 50 eyes of the propranolol group, as opposed to 7 
out of 52 eyes in the control group. There was no progres-
sion to stage 4 ROP in the propranolol group, while it was 
observed in 4 out of 26 infants/4 out of 52 eyes in the con-
trol group. Five of the 26 newborns treated with propran-
olol were reported to have had serious adverse effects (hy-
potension, bradycardia) in conjunction with episodes of 
sepsis, anesthesia induction, or tracheal stimulation.
 These two trials are small, and they are partly marred 
by statistical flaws and unclear methodological issues. 
Moreover, they differ with respect to inclusion criteria, 
dose, and – most strikingly – duration of oral propranolol 
administration. However, the effect sizes of the trials are 
very similar. Combining the published data would result 
in 6 infants with ROP interventions out of 35 proprano-
lol-treated infants, as opposed to 14 out of 36 control in-
fants (p = 0.055, relative risk 0.44, 95% CI: 0.19–1.02), 
translating to a number needed to treat of 5. Thus, pre-
vention of ROP progression towards threshold disease by 
oral propranolol remains a promising avenue of research. 
It is also an important one as many ROP infants treated 
with laser photocoagulation still have poor visual out-
come due to ablation of the peripheral retina and severe 
myopia  [20] , while intravitreal injections of anti-VEGF 
agents such bevacizumab, ranibizumab, or pegaptanib, 
all of which are off-label in infants, carry a risk of late re-
currences, and may aggravate retinal detachment when 
used in advanced stages of ROP. Of note, intravitreal bev-
acizumab has been reported to reduce circulating VEGF 
concentrations in human infants  [21] , while circulating 
VEGF did not differ between infants receiving oral pro-
pranolol or controls  [19] .
 Ongoing Trials 
 An ongoing randomized placebo-controlled trial is 
currently recruiting preterm infants with a gestational age 
between 26 and 32 weeks at 1 week of chronological age 
to preventive treatment with oral propranolol (1 mg/kg/
day in two divided doses) or placebo until complete vas-
cularization or 37 weeks’ gestational age (CTRI/2013/
11/004131). Propranolol eye drops are being investigated 
as a treatment of progressive ROP in experimental ani-
mals  [22] and in a trial with preterm human infants 
(NCT01079715). A formal Cochrane review into the is-
sue has been launched (S. Kämpfen, K. Jost, R. Neumann 
and S. Schulzke). The limited evidence available to date 
does not permit drawing any firm conclusions regarding 
the use of propranolol to treat or prevent progression of 
ROP, and sufficiently powered well-designed interven-
tional trials are urgently needed.
 Future Research  
 There are intriguing case reports of successful admin-
istration of oral propranolol to adult patients with diffuse 
choroidal hemangiomas displaying exudative retinal de-
tachment  [23] or with central serous choriodopathy  [24] . 
An open-label study investigating oral propranolol in 
adult patients with proliferative diabetic retinopathy and 
neovascularization has started recruitment. Until now, 
therapies for proliferative retinopathies are based on local 
interventions, and exploring the possibilities of systemi-
cally administered drugs has become an exciting area of 
research. Hopefully, it will also lead to improved long-
term outcome of infants with ROP.
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